Continuous infusion therapy in haemophilia

Summary. The application of coagulation factor therapy by continuous infusion (CI) was first suggested by Brinkhous in the early 1950s [ 1 ]. The recent introduction of this mode of therapy to everyday practice was made possible after the demonstration of a good stability of most factor concentrates which were also found safe regarding potential bacterial contamination. Other developments included a better understanding of the pharmacokinetics of factors concentrates as well as the availability of a new delivery system. Continuous infusion was shown to be superior to bolus injection (BI) in achieving a stabile haemostatic effect, in the prevention of post‐operative bleeding and was found to save between 20–50% in the required factor. This mode of therapy was found effective in haemophilia A and B as well as among patients with inhibitors to FVIII and with von Willebrand disease (vWD).

[1]  D. S. Houston,et al.  Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors , 1997, American journal of hematology.

[2]  K. Khair,et al.  Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease , 1997, Blood Coagulation and Fibrinolysis.

[3]  S. Schulman,et al.  Continuous infusion instead of bolus injections of factor concentrate? , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  S. Schulman,et al.  Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  S. Schulman,et al.  Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  S. Schulman,et al.  Feasibility of Using Recombinant Factor VIIa in Continuous Infusion , 1996, Thrombosis and Haemostasis.

[7]  C. Miller,et al.  In vitro factor VIII recovery during the delivery of ultra‐pure factor VIII concentrate by continuous infusion , 1996, American journal of hematology.

[8]  S. Travis,et al.  Postoperative Management of Hemophilia A and Low Titer Inhibitor at Home Using Factor VIII Continuous Infusion , 1996, Clinical pediatrics.

[9]  S. Schulman,et al.  The feasibility of using concentrates containing factor IX for continuous infusion , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  S. Schulman,et al.  Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. , 1994, Thrombosis and haemostasis.

[11]  K. Fukutake,et al.  Substantial expression of glycoproteins IX and V on the platelet surface from a patient with Bernard‐Soulier syndrome , 1994, British journal of haematology.

[12]  S. Schulman,et al.  Stability of factor VIII concentrates after reconstitution , 1994, American journal of hematology.

[13]  P. Mannucci,et al.  Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease , 1993, Thrombosis and Haemostasis.

[14]  E. Gordon,et al.  Lingual Hemorrhage in a Patient with Hemophilia A Complicated by a High Titer Inhibitor: Management by Continuous Infusion of Monoclonal Antibody‐Purified Factor VIII , 1993, The American journal of pediatric hematology/oncology.

[15]  S. Schulman,et al.  Adjusted dose continuous infusion of factor VIII in patients with haemophilia A , 1992, British journal of haematology.

[16]  M. Morfini,et al.  The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX , 1991, Thrombosis and Haemostasis.

[17]  R. Bona,et al.  Continuous infusion of monoclonal antibody‐purified factor VIII , 1991, American journal of hematology.

[18]  R. Weinstein,et al.  The use of continuous infusion of factor concentrates in the treatment of hemophilia , 1989, American journal of hematology.

[19]  D. Noe,et al.  Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. , 1986, Blood.

[20]  W. Hathaway,et al.  Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A , 1984, American journal of hematology.

[21]  D. Doyle,et al.  Elective cardiac operation in a patient with severe hemophilia and acquired factor VIII antibodies. , 1984, The Journal of thoracic and cardiovascular surgery.

[22]  G. White,et al.  Treatment of Anti-Factor VIII Antibodies , 1977, Thrombosis and Haemostasis.

[23]  C. Mcmillan,et al.  Continuous Intravenous Infusion of Factor VIII in Classic Haemophilia , 1970, British journal of haematology.